gms | German Medical Science

63rd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Japanese Neurosurgical Society (JNS)

German Society of Neurosurgery (DGNC)

13 - 16 June 2012, Leipzig

Podoplanin expression influences survival in glioblastoma

Meeting Abstract

  • M. Guentchev - Department of Neurosurgery, Klinikum Idar-Oberstein, Idar-Oberstein, Germany
  • S. Natchev - Department of Neuropathology, St. Ivan Rilski Hospital, Sofia, Bulgaria
  • P. Birner - Comprehensive Cancer Center - CNS unit, Medical University Vienna, Vienna, Austria
  • J. Tüttenberg - Department of Neurosurgery, Klinikum Idar-Oberstein, Idar-Oberstein, Germany

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocFR.01.09

DOI: 10.3205/12dgnc173, URN: urn:nbn:de:0183-12dgnc1732

Published: June 4, 2012

© 2012 Guentchev et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Podoplanin is a type-I transmembrane glycoprotein. Several reports suggest a role of podoplanin in tissue development and repair as well as in carcinogenesis. Podoplanin is widely expressed in tumours of the CNS, including ependymal tumours, choroid plexus papillomas, meningeomas, pilocytic astrocytomas and glioblastomas. In malignant astrocytic tumours, increased expression of podoplanin correlated with higher histological tumour malignancy. No data on Podoplanin influencing survival in glioma have been published yet.

Methods: Here we immunohistochemically assessed podoplanin expression using a monoclonal antibody in formalin-fixed, paraffin-embedded specimens of 80 patients with supratentorial glioblastomas and 21 patients with supratentorial grade II and III gliomas. Cases were rated either as positive or negative.

Results: Podoplanin was expressed in 1/13 grade II gliomas, 2/8 grade III gliomas, and 54/80 glioblastomas. Patients with glioblastomas expressing podoplanin had significantly shorter overall survival than those without (p = 0.01, log rank test).

Conclusions: Our findings provide evidence that Podoplanin is linked with clinically more aggressive behaviour in glioblastomas and suggest that podoplanin inhibition could be considered as a possible therapeutic approach in malignant gliomas.